Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia

Mayo Clinic Proceedings

Volumn 76, Issue 10, 2001, Pages 1039-1046

  Vella, Adrian ^a   Pineda, Alvaro A ^a   O’brien, Timothy ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

ACEI = angiotensin converting enzyme inhibitor; Apo B = apolipoprotein B; DFPP = double filtration plasmapheresis; FH = familial hypercholesterolemia; HDL = high density lipoprotein; HELP = heparin extracorporeal LDL precipitation; HMG CoA = 3 hydroxy 3 methylglutaryl coenzyme A; LDL = low density lipoprotein; NCEP = National Cholesterol Education Program

Indexed keywords

BRADYKININ; DEXTRAN SULFATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANGINA PECTORIS; ANTICOAGULATION; APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; FAMILIAL HYPERCHOLESTEROLEMIA; GLOMERULONEPHRITIS; HEART TRANSPLANTATION; HEMOLYSIS; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PLASMAPHERESIS;

EID: 0034774144     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.10.1039     Document Type: Article

References (79)

1. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: Importance of diet, exercise, weight control, and drug therapy
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival study (4S)
4. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
5. Extracorporeal LDL cholesterol removal: Role of LDL-pheresis in combination with other hypolipidemic therapy to regress vascular disease
6. Familial hypercholesterolemia
7. Experiences with the homozygous cases of familial hypercholesterolemia: A report of 52 patients
8. Cadiovascular complications of homozygous familial hypercholesterolaemia
9. Cardiovascular pathology in hyperlipoproteinemia: Anatomic observations in 42 necropsy patients with normal or abnormal serum lipoprotein patterns
10. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
11. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow-up report from the POSCH: Program on the Surgical Control of the Hyper-lipidemias
12. Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia
13. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia
14. Heart-liver transplantation in a patient with familial hypercholesterolaemia
15. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia
16. Plasma exchange in the management of homozygous familial hypercholesterolaemia
17. Assessment of long-term plasma-exchange for familial hypercholesterolaemia
18. Mobilisation of tissue cholesterol by apheresis
19. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia: Results of a multicenter LDL apheresis study
20. Plasma exchange for hypercholesterolaemia
21. Indications for low-density lipoprotein apheresis
22. Effect of instensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia
23. Successful plasmapheresis in a 4-year-old child with homozygous familial hypercholesterolemia
24. Assessment of currently available low-density lipoprotein apheresis systems
25. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia
26. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis)
27. Adsorption of lipoprotein containing apolipoprotein-B through plasma separation for treatment of familial hypercholesterolemia
28. Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100
29. Removal of low-density lipoproteins in patients by extracorporeal immunoadsorption
30. Removal of low-density lipoproteins (LDL) and fibrinogen by precipitation with heparin at low pH: Clinical application and experience
31. DALI - The first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: Procedure and clinical results
32. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system
33. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia
34. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors
35. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes
36. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis
37. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors
38. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors
39. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system
40. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption
41. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis
42. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system
43. Selective removal of plasma low density lipoprotein with the HELP system: Biweekly versus weekly therapy
44. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia
45. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy
46. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia
47. Acute effects of LDL-apheresis on cholesterol oxidation products and antioxidants in plasma and lipoproteins of patients with familial hypercholesterolemia
48. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis
49. Clinical reality of lowering total and LDL cholesterol
50. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy
51. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease, I: Evaluation of safety and cholesterol-lowering effects during the first 12 months
52. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease, II: Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease
53. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: A multicenter study
54. Familial hypercholesterolaemia regression study: A randomised trial of low-density-lipoprotein apheresis
55. Low-density-lipoprotein apheresis
56. Low-density-lipoprotein apheresis
57. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease: LDL-Apheresis Atherosclerosis Regression Study (LAARS)
58. LDL-Apheresis Atherosclerosis Regression Study (LAARS): Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis
59. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia
60. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: Change in prostacyclin and effect on ischemic symptoms
61. LDL apheresis in atherosclerotic disease with hyperlipidemia
62. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease?
63. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia
64. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia
65. Improvement of coronary vasodilatation capacity through single LDL apheresis
66. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
67. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis
68. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART)
69. Effects of LDL apheresis on restenosis after angioplasty
70. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients
71. Relationship of immunosuppression and serum lipids to the development of coronary arterial disease in the transplanted heart
72. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis
73. Regression of transplant coronary artery disease during chronic HELP therapy: A case study
74. Ongoing clinical trials of lipid reduction therapy in patients with renal disease
75. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy
76. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome
77. Complete remission of the nephrotic syndrome due to focal glomerular sclerosis achieved with low density lipoprotein adsorption alone
78. Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis
79. Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy